Archives
-
Minocycline HCl in Retinal Microglia Assays
2026-09-12
Use Minocycline HCl as a controlled microglial-activity perturbation in retinal amyloid-clearance workflows, not merely as an antibiotic. This guide translates 40-Hz flicker findings into practical controls, formulation steps, readouts, and troubleshooting decisions for inflammation and neuroprotection studies.
-
Nicotinamide Riboside Chloride in RGC Research
2026-09-11
Nicotinamide Riboside Chloride (NIAGEN) can be tested as a metabolic support layer alongside chemically defined iPSC-to-retinal ganglion cell differentiation. This article translates NAD+ biology into practical assay design, control selection, and troubleshooting for metabolic dysfunction research and neurodegenerative disease models.
-
Nicotinamide Riboside Chloride in RGC Research
2026-09-11
Nicotinamide Riboside Chloride (NIAGEN) adds a controllable NAD+ metabolism variable to chemically defined retinal ganglion cell workflows. Use it to connect lineage differentiation with oxidative metabolism modulation while preserving the dual SMAD–Wnt framework that improves RGC reproducibility.
-
Prochlorperazine-Induced Hemidystonia Mimicking Stroke
2026-09-10
This 2015 case report describes unilateral hemidystonia after newly initiated prochlorperazine therapy in a pregnant patient whose presentation triggered an acute stroke response. The rapid response to intravenous diphenhydramine, negative brain MRI, and symptom recurrence during observation illustrate how medication history and evolving extrapyramidal signs can prevent misclassification of a stroke mimic.
-
BMS 599626 dihydrochloride Workflows
2026-09-10
BMS 599626 dihydrochloride provides a focused way to dissect EGFR/HER2 signaling, connect receptor inhibition with cancer cell proliferation inhibition, and test pathway dependence in breast and lung cancer models. This guide combines dose–response design, senescence-aware controls, translational readouts, and troubleshooting for more reproducible experiments.
-
Central Control of Opioid Mechanical Hypersensitivity
2026-09-09
Yin et al. identify a brain-to-spinal opioid circuit linking MOR-expressing neurons in the lateral parabrachial nucleus, dynorphin neurons in the paraventricular hypothalamus, and KOR-expressing GABAergic neurons in the spinal dorsal horn. The study shows that this pathway regulates morphine-induced mechanical hypersensitivity and analgesic tolerance, providing a circuit-level explanation for pain that can emerge during repeated opioid exposure.
-
Bifendate (DDB): Practical Liver Research Workflows
2026-09-09
Build reproducible liver disease experiments with Bifendate (DDB), from solvent preparation and hepatocyte dosing to lipid and autophagy readouts. Its distinctive value is the ability to connect hepatoprotection, hepatic lipid reduction, and multi-stage autophagy inhibition in one preclinical workflow.
-
Dovitinib and ERK: Designing Causal Cancer Assays
2026-09-08
Dovitinib and TKI-258 offer a powerful framework for studying RTK-driven signaling and apoptosis. This guide connects multitarget pharmacology with ERK-dependent interferon-gamma biology to improve causal assay design across cancer models.
-
MG-132: Proteostasis-Aware Assay Design
2026-09-08
MG-132 is more than a proteasome inhibitor: it is a timed perturbation tool for connecting ubiquitin signaling, proteotoxic stress, apoptosis, and cell-cycle behavior. This guide integrates product biology with the 2025 UFD1s study to improve assay interpretation and experimental design.
-
Chronic Stress, Mitochondria, and Depression-Like Behavior
2026-09-07
A 2025 Psychoneuroendocrinology study used chronic unpredictable mild stress and intracerebroventricular MnTBAP to connect mitochondrial dysfunction with neuroinflammation and depression-like behavior in rats. Its rescue experiment strengthens the case for a functional role of mitochondrial redox imbalance, while also highlighting the limits of translating pharmacological findings from an animal model to human depression.
-
In Vitro Metrics for Cancer Drug Responses
2026-09-07
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different combinations of proliferation arrest and cell death. Its central contribution is a more time-aware framework for interpreting in vitro drug responses and comparing therapeutic effects without treating a single viability endpoint as a direct measure of killing.
-
Phillygenin in Diabetic Nephropathy: Mechanistic Study
2026-09-05
This study shows that phillygenin protects against diabetic nephropathy in high-glucose podocyte models and db/db mice by suppressing TLR4/MyD88/NF-κB-associated inflammation while restoring PI3K/AKT/GSK3β signaling. Its principal contribution is the integration of transcriptomic screening, pathway validation, and renal functional outcomes into a preclinical mechanism framework.
-
Malate as a Flux-Control Assay for Tumor Metabolism
2026-09-04
Malate and (S)-2-hydroxysuccinic acid provide a practical way to interrogate mitochondrial redox, TCA-cycle flux, and metabolic adaptation. This guide translates recent PDHA1 succinylation findings into assay controls that distinguish correlation from mechanism.
-
CPI-613, PDH Signaling, and Cuproptosis Assays
2026-09-04
CPI-613 is a mitochondrial metabolism inhibitor that connects PDH and KGDH activity with apoptosis assay design. This article explains how recent PDHA1–acetylation and cuproptosis findings can sharpen tumor cell metabolism studies without overstating the evidence.
-
Ruxolitinib Targets DRP1-Linked Death in ATC
2026-09-03
The reference study identifies a mechanistic connection between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, and two forms of regulated cell death in anaplastic thyroid carcinoma. Its findings suggest that ruxolitinib suppresses STAT3-driven DRP1 transcription, producing mitochondrial fission deficiency followed by caspase-dependent apoptosis and GSDME-mediated pyroptosis.